Patients who were treated for abdominal aortic aneurysm with Medtronic's AneuRx stent-graft system had higher death rates after five years compared with those who underwent conventional surgery, the FDA said in a public-health notice. A company spokesman said that the FDA's data leave out information about short-term mortality and that the device "performs better compared to open surgery in late AAA-related deaths."

Related Summaries